Literature DB >> 3119211

Mesna--a short review.

I C Shaw1, M I Graham.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3119211     DOI： 10.1016/0305-7372(87)90041-7

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN： 0305-7372            Impact factor:   12.111


× No keyword cloud information.
  26 in total

Review 1.  Ifosfamide/mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer.

Authors:  K L Dechant; R N Brogden; T Pilkington; D Faulds
Journal:  Drugs       Date:  1991-09       Impact factor: 9.546

2.  The stability of mesna in beverages and syrup for oral administration.

Authors:  M P Goren; B A Lyman; J T Li
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

3.  False-positive ketone tests: a bedside measure of urinary mesna.

Authors:  M P Goren; C B Pratt
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

4.  The challenges of solid tumor for designer CAR-T therapies: a 25-year perspective.

Authors:  Richard P Junghans
Journal:  Cancer Gene Ther       Date:  2017-03       Impact factor: 5.987

Review 5.  Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites.

Authors:  T Kerbusch; J de Kraker; H J Keizer; J W van Putten; H J Groen; R L Jansen; J H Schellens; J H Beijnen
Journal:  Clin Pharmacokinet       Date:  2001-01       Impact factor: 6.447

Review 6.  Treatment of vasculitis.

Authors:  H G Taylor; A Samanta
Journal:  Br J Clin Pharmacol       Date:  1993-02       Impact factor: 4.335

7.  Interaction between cisplatin and mesna in mice.

Authors:  R T Dorr; K Lagel
Journal:  J Cancer Res Clin Oncol       Date:  1989       Impact factor: 4.553

8.  Oral bioavailability of mesna tablets.

Authors:  B Stofer-Vogel; T Cerny; M Borner; B H Lauterburg
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

9.  Placebo-controlled double-blind comparative study on the preventive efficacy of mesna against ifosfamide-induced urinary disorders.

Authors:  M Fukuoka; S Negoro; N Masuda; K Furuse; M Kawahara; N Kodama; H Ikegami; S Nakamura; H Nishio; T Ohnoshi
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

Review 10.  Dosing and side-effects of ifosfamide plus mesna.

Authors:  W P Brade; K Herdrich; U Kachel-Fischer; C E Araujo
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.